SPECIAL NOTICE
99 -- Special Notice Announcing the Pre-Proposal Conference for the National Cancer Institute�s Federally Funded Research and Development Center (FFRDC)/Frederick National Laboratory for Cancer Research (FNLCR)
- Notice Date
- 10/11/2022 11:45:26 AM
- Notice Type
- Special Notice
- Contracting Office
- NIH NCI ROCKVILLE MD 20852 USA
- ZIP Code
- 20852
- Solicitation Number
- HHS-NIH-NCI-SN-MOSB-75N91020R00062-28
- Archive Date
- 11/16/2022
- Point of Contact
- Lisa Bielen, Don Mills
- E-Mail Address
-
FNLCR_ACQinfo@mail.nih.gov, FNLCR_ACQinfo@mail.nih.gov
(FNLCR_ACQinfo@mail.nih.gov, FNLCR_ACQinfo@mail.nih.gov)
- Description
- PURPOSE: The National Cancer Institute (NCI) is virtually hosting the ""NCI�s FFRDC Pre-Proposal Conference"" (PPC) for the purpose of providing information concerning the Government's requirements which may be helpful in the preparation of proposals. �This conference is scheduled for November 15, 2022.� This event will be a virtual conference and will consist primarily of presentations providing information on the background of the FFRDC, Topics for Special Consideration, and Solicitation Overview/Breakdown.� Any questions submitted during the conference will be collected and may be answered at the discretion of the government through SAM.gov. � VIRTUAL CONFERENCE INFORMATION: Date: November 15, 2022 Start Time: 9:00AM EST Please follow the below link to register for this event. https://forms.office.com/g/edQz2cY1Pp Registration for this event will close on November 14, 2022, at 5:00 PM EST. BACKGROUND: The NCI�s FFRDC provides rapid response capabilities and one-of-a-kind resources for the biomedical research community including NCI, NIH, other Federal Agencies, and National Missions. The NCI�s FFRDC is a Government-Owned Contractor-Operated (GOCO) research facility with a unique array of research support and advanced technologies, whose purpose is to bridge the gaps starting with discovery and traversing through healthcare delivery. The NCI�s FFRDC facilitates and accelerates the development of new technologies and prototype treatments for patients and paves the way for these advances to enter first-in-human clinical trials for investigation, regulatory approval, and commercial access via the FNLCR). Entities authorized to operate, manage, or administer an FFRDC include a university, a consortium of universities, other not-for-profit or nonprofit organizations, industrial firms as autonomous organizations (identified separately from any parent organization), or industry/academia partnerships. For more information, please refer to the website at http://frederick.cancer.gov/. ADDITIONAL INFORMATION: Additional information concerning the competitive process for the contract will be announced on https://sam.gov/ as well as at the FNLCR Acquisition Portal:� https://www.cancer.gov/about-nci/contracts/fnlcr-acquisitions/fedbizopps-notices. The information posted to SAM.gov takes precedence over information provided elsewhere and serves as the Government�s official government-wide point of entry (GPE). If you have questions, please email the FNLCR Acquisition Team at: FNLCR_ACQinfo@nih.gov �(FNLCR_ACQinfo@nih.gov). THIS IS A SPECIAL NOTICE. This is NOT a solicitation for proposals, proposal abstracts, capability statements, or quotations. The purpose of this Special Notice is to announce the NCI�s FFRDC Industry Day.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/945fdce912b54df793f1083b076de897/view)
- Record
- SN06490474-F 20221013/221011230056 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |